ArticlemSphere2018
Mechanism of High-Level Daptomycin Resistance in
Open access · goldAbstract read
In one paragraph
Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Antimicrobial treatment of Corynebacterium striatum invasive infections: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2021Pooled it
- The Testing and Characterization of the Bacterial Response to Novel Lipid Ether Amine-Based Antibiotics.bioRxiv : the preprint server for biology · 2026Article
- Rapid acquisition of daptomycin resistance in aASM case reports · 2025Article
- Article
- Daptomycin forms a stable complex with phosphatidylglycerol for selective uptake to bacterial membrane.eLife · 2025Article
- Emergence of Daptomycin Nonsusceptibility and Treatment Failure in Patients WithOpen forum infectious diseases · 2024Article
- Rising prevalence and drug resistance ofFrontiers in cellular and infection microbiology · 2024Review
- Even a single positive blood culture may matter - A case of prosthetic valve infective endocarditis caused byIDCases · 2024Article
- Clinical Profile of MonomicrobialOpen forum infectious diseases · 2022Article
- The challenge of antibiotic selection in prosthetic joint infections due to Corynebacterium striatum: a case report.BMC infectious diseases · 2022Article
- Polymyxin and lipopeptide antibiotics: membrane-targeting drugs of last resort.Microbiology (Reading, England) · 2022Review
- Detection of in-frame mutation by IS30-family insertion sequence in the phospholipid phosphatidylglycerol synthase gene (pgsA2) of high-level daptomycin-resistant Corynebacterium striatum.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Wide spread and diversity of mutation in the gyrA gene of quinolone-resistant Corynebacterium striatum strains isolated from three tertiary hospitals in China.Annals of clinical microbiology and antimicrobials · 2021Article
- Binding Studies Reveal Phospholipid Specificity and Its Role in the Calcium-Dependent Mechanism of Action of Daptomycin.ACS infectious diseases · 2021Article
- Treat Me Well or Will Resist: Uptake of Mobile Genetic Elements Determine the Resistome ofInternational journal of molecular sciences · 2021Review
- Evaluating the Rapid Emergence of Daptomycin Resistance inJournal of clinical microbiology · 2021Article
- Infective Endocarditis Due toOpen forum infectious diseases · 2021Article
- Current Evidence forMicroorganisms · 2021Review
- The phosphatidylglycerol phosphate synthase PgsA utilizes a trifurcated amphipathic cavity for catalysis at the membrane-cytosol interface.Current research in structural biology · 2021Article
- Engineered Cationic Antimicrobial Peptides (eCAPs) to Combat Multidrug-Resistant Bacteria.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Nicholas K Goldner *Edison Family Center for Genome Sciences & Systems Biology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Christopher Bulow *Edison Family Center for Genome Sciences & Systems Biology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0001-5784-6662
Kevin ChoDepartment of Chemistry, Washington University in St. Louis, St. Louis, Missouri, USA.
Meghan WallaceDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Fong-Fu HsuDivision of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St. Louis, Missouri, USA.
Gary J PattiDepartment of Chemistry, Washington University in St. Louis, St. Louis, Missouri, USA.
C A BurnhamDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-1137-840X
Paul SchlesingerDepartment of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
Gautam DantasEdison Family Center for Genome Sciences & Systems Biology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA dantas@wustl.edu.
Washington University in St. Louis · US
Funding
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2MWU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1MTrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0MINSTITUTIONAL TRAINING GRANT IN GENOMIC SCIENCET32HG000045 · NHGRI · WASHINGTON UNIVERSITY · PI MICHAEL R BRENT, Barak A Cohen · 1997 to 2026
$8.4MDeveloping Metabolomic Technologies to Advance Environmental Exposure AnalysisR35ES028365 · NIEHS · WASHINGTON UNIVERSITY · PI PATTI, GARY J · 2017 to 2024
$5.9MSTRUCTURAL, MECHANISTIC, & EVOLUTIONARY CHARACTERIZATION OF TETRACYCLINE DESTRUCTASESU01AI123394 · NIAID · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, WENCEWICZ, TIMOTHY ADAM · 2020 to 2025
$4.1MPHYLOGENOMIC, TRANSCRIPTOMIC, VIROMIC, AND IMMUNOPROTEOMIC DETERMINANTS OF NECROTIZING ENTEROCOLITISR01HD092414 · NICHD · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, TARR, PHILLIP I · 2017 to 2021
$3.0MSTRUCTURAL, MECHANISTIC, & EVOLUTIONARY CHARACTERIZATION OF TETRACYCLINE DESTRUCTASESR01AI123394 · NIAID · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM, WENCEWICZ, TIMOTHY ADAM · 2016 to 2019
$2.7MESTABLISHMENT AND DYNAMICS OF ANTIBIOTIC RESISTANCE RESERVOIRS IN DEVELOPING INTER01GM099538 · NIGMS · WASHINGTON UNIVERSITY · PI DANTAS, GAUTAM · 2013 to 2016
$1.2MNHGRI NIH HHS T32 HG000045NIAID NIH HHS R01 AI123394NIAID NIH HHS U01 AI123394NICHD NIH HHS R01 HD092414NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK056341NIEHS NIH HHS R35 ES028365NIGMS NIH HHS P41 GM103422NIGMS NIH HHS R01 GM099538
Abstract
Daptomycin, a last-line-of-defense antibiotic for treating Gram-positive infections, is experiencing clinical failure against important infectious agents, including
Indexed as
Drug Resistance, BacterialAnti-Bacterial AgentsCell MembraneCorynebacteriumCorynebacterium InfectionsDaptomycinHumansMicrobial Sensitivity TestsMutationPhosphatidylglycerolsTransferases (Other Substituted Phosphate Groups)Anti-Bacterial AgentsCDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferaseDaptomycinPhosphatidylglycerolsTransferases (Other Substituted Phosphate Groups)antimicrobial resistanceartificial liposomesCorynebacteriumdaptomycingenomicslipidomicsphosphatidylglycerolsurface plasmon resonancetranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.